WO2001010468A3 - Drug-carrier complexes and methods of use thereof - Google Patents

Drug-carrier complexes and methods of use thereof Download PDF

Info

Publication number
WO2001010468A3
WO2001010468A3 PCT/US2000/021762 US0021762W WO0110468A3 WO 2001010468 A3 WO2001010468 A3 WO 2001010468A3 US 0021762 W US0021762 W US 0021762W WO 0110468 A3 WO0110468 A3 WO 0110468A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
drug
drugs
compositions
cells
Prior art date
Application number
PCT/US2000/021762
Other languages
French (fr)
Other versions
WO2001010468A2 (en
Inventor
Mikhail I Papisov
Original Assignee
Gen Hospital Corp
Mikhail I Papisov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Mikhail I Papisov filed Critical Gen Hospital Corp
Priority to AU67626/00A priority Critical patent/AU6762600A/en
Priority to EP00955415A priority patent/EP1206285A2/en
Priority to JP2001514984A priority patent/JP4813712B2/en
Publication of WO2001010468A2 publication Critical patent/WO2001010468A2/en
Publication of WO2001010468A3 publication Critical patent/WO2001010468A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Drug-carrier complexes, drug carriers, pharmaceutical formulations, methods of delivery drugs to an organism or tissue culture, methods of increasing the solubility of a substance, targeted carriers, drug delivery systems and implants are described. The compositions and methods of the invention include forming complexes having reversible associations between nucleotides and drugs. The compositions and methods of the invention can be employed to target drugs to cells, organisms or combinations of cells to treat and to study the underlying mechanisms of diseases, and to test drug candidates.
PCT/US2000/021762 1999-08-09 2000-08-09 Drug-carrier complexes and methods of use thereof WO2001010468A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU67626/00A AU6762600A (en) 1999-08-09 2000-08-09 Drug-carrier complexes and methods of use thereof
EP00955415A EP1206285A2 (en) 1999-08-09 2000-08-09 Drug-carrier complexes and methods of use thereof
JP2001514984A JP4813712B2 (en) 1999-08-09 2000-08-09 Drug-carrier complex and method of using the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14791999P 1999-08-09 1999-08-09
US60/147,919 1999-08-09

Publications (2)

Publication Number Publication Date
WO2001010468A2 WO2001010468A2 (en) 2001-02-15
WO2001010468A3 true WO2001010468A3 (en) 2002-01-17

Family

ID=22523463

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/021762 WO2001010468A2 (en) 1999-08-09 2000-08-09 Drug-carrier complexes and methods of use thereof

Country Status (4)

Country Link
EP (1) EP1206285A2 (en)
JP (2) JP4813712B2 (en)
AU (1) AU6762600A (en)
WO (1) WO2001010468A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9555119B2 (en) 2012-11-05 2017-01-31 Surmodics, Inc. Composition and method for delivery of hydrophobic active agents

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
DE60323936D1 (en) 2002-01-14 2008-11-20 Gen Hospital Corp BIOABEAABLE POLYCETALES, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE
CA2492803C (en) 2002-07-19 2013-11-05 The General Hospital Corporation Oxime conjugates and methods for their formation and use
ATE507845T1 (en) 2003-09-05 2011-05-15 Gen Hospital Corp POLYACETAL DRUG CONJUGATES AS A RELEASE SYSTEM
WO2009002993A1 (en) 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
CL2009002167A1 (en) 2008-12-10 2010-10-15 Mersana Therapeutics Inc Pharmaceutical formulation for intravenous administration comprising a compound derived from biocompatible and biodegradable camptothecin-polymer conjugates, a stabilizing agent, one or more buffers and a surfactant, useful for the treatment of cancer.
CA2760187C (en) 2009-04-28 2018-01-02 Ralph A. Chappa Devices and methods for delivery of bioactive agents
US10213529B2 (en) 2011-05-20 2019-02-26 Surmodics, Inc. Delivery of coated hydrophobic active agent particles
US9757497B2 (en) 2011-05-20 2017-09-12 Surmodics, Inc. Delivery of coated hydrophobic active agent particles
US9861727B2 (en) 2011-05-20 2018-01-09 Surmodics, Inc. Delivery of hydrophobic active agent particles
JP5926374B2 (en) 2011-06-10 2016-05-25 メルサナ セラピューティクス，インコーポレイティド Protein-polymer-drug conjugate
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
JP5378469B2 (en) * 2011-08-11 2013-12-25 学校法人 日本歯科大学 Medicinal drugs
US8785569B2 (en) * 2011-11-22 2014-07-22 Original Biomedicals Co., Ltd. Drug carrier with chelating complex micelles and the application thereof
US11246963B2 (en) 2012-11-05 2022-02-15 Surmodics, Inc. Compositions and methods for delivery of hydrophobic active agents
ES2726850T3 (en) 2013-10-11 2019-10-09 Mersana Therapeutics Inc Protein-polymer-drug conjugates
CN105813655B (en) 2013-10-11 2022-03-15 阿萨纳生物科技有限责任公司 Protein-polymer-drug conjugates
JP6676650B2 (en) * 2015-03-13 2020-04-08 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． Conjugates for treating diseases
US11474106B2 (en) 2015-07-08 2022-10-18 Lawrence Livermore National Security, Llc Methods for cytotoxic chemotherapy-based predictive assays
CN109890393A (en) * 2016-10-03 2019-06-14 Eos生物科学公司 Function RNA and small molecule treatment compound and nano particle delivery medium
US10898446B2 (en) 2016-12-20 2021-01-26 Surmodics, Inc. Delivery of hydrophobic active agents from hydrophilic polyether block amide copolymer surfaces
WO2018132766A1 (en) * 2017-01-12 2018-07-19 The Regents Of The University Of California Cytotoxic chemotherapy-based predictive assays for acute myeloid leukemia
WO2021118927A1 (en) * 2019-12-13 2021-06-17 Insideoutbio, Inc. Methods and compositions for targeted delivery of nucleic acid therapeutics

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999030561A1 (en) * 1997-12-18 1999-06-24 Nexstar Pharmaceuticals, Inc. Nucleotide-based prodrugs
WO2000050050A1 (en) * 1999-02-23 2000-08-31 Isis Pharmaceuticals, Inc. Multiparticulate formulation
WO2000078285A1 (en) * 1999-06-18 2000-12-28 University Of Medicine And Dentistry Of New Jersey Controlled release of therapeutics by in-situ entrapment by matrix cross-linking

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1440626A (en) * 1973-05-02 1976-06-23 Farmaceutici Italia
DE3568583D1 (en) * 1985-08-29 1989-04-13 Berol Kemi Ab A carrier with an immobilised, biologically active substance, a method for its preparation, and the use thereof
US5811510A (en) * 1995-04-14 1998-09-22 General Hospital Corporation Biodegradable polyacetal polymers and methods for their formation and use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999030561A1 (en) * 1997-12-18 1999-06-24 Nexstar Pharmaceuticals, Inc. Nucleotide-based prodrugs
WO2000050050A1 (en) * 1999-02-23 2000-08-31 Isis Pharmaceuticals, Inc. Multiparticulate formulation
WO2000078285A1 (en) * 1999-06-18 2000-12-28 University Of Medicine And Dentistry Of New Jersey Controlled release of therapeutics by in-situ entrapment by matrix cross-linking

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HASHIDA M ET AL: "Targeted delivery of plasmid DNA complexed with galactosylated poly(l-lysine)", JOURNAL OF CONTROLLED RELEASE,ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM,NL, vol. 53, no. 1-3, 30 April 1998 (1998-04-30), pages 301 - 310, XP004121281, ISSN: 0168-3659 *
See also references of EP1206285A2 *
VERONESE F M ET AL: "Bioconjugation in pharmaceutical chemistry", IL FARMACO,ROME,IT, vol. 54, 30 August 1999 (1999-08-30), pages 497 - 516, XP002127817 *
ZANGEMEISTER-WITTKE U ET AL: "SYNERGIC CYTOTOXICITY OF BCL-2 ANTISENSE OLIGODEOXYNUCLEOTIDES AND ETOPOSIDE, DOXORUBICIN AND CISPLATIN ON SMALL-CELL LUNG CANCER CELLLINES", BRITISH JOURNAL OF CANCER,LONDON,GB, vol. 78, no. 8, 1998, pages 1035 - 1042, XP000965123, ISSN: 0007-0920 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9555119B2 (en) 2012-11-05 2017-01-31 Surmodics, Inc. Composition and method for delivery of hydrophobic active agents

Also Published As

Publication number Publication date
JP4813712B2 (en) 2011-11-09
WO2001010468A2 (en) 2001-02-15
EP1206285A2 (en) 2002-05-22
JP2011231122A (en) 2011-11-17
JP2003506417A (en) 2003-02-18
AU6762600A (en) 2001-03-05

Similar Documents

Publication Publication Date Title
WO2001010468A3 (en) Drug-carrier complexes and methods of use thereof
BRPI0413427A (en) active pyridylpyrrole derivatives as kinase inhibitors
MXPA06000302A (en) Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them.
CA2446435A1 (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
NZ543661A (en) Pyrazolo-quinazoline derivatives having antitumor activity and process for their preparation
WO2005072061A3 (en) Conjugates for cancer therapy and diagnosis
TNSN07290A1 (en) Gastroresistant pharmaceutical formulations containing rifaximin
WO2003099771A3 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
CN102480945A (en) Skin treatment compositions
IL160015A0 (en) Use of biologically active hiv-1 tat, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases
GB0211649D0 (en) Organic compounds
EP2233156A3 (en) Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
WO2007079082A3 (en) Gastric release pulse system for drug delivery
HUP0203590A2 (en) Remedies for diseases in association with decrease in bone mass
CY1109695T1 (en) Oxalate degradation microorganisms or oxalate degradation enzyme for the prevention of oxalate-related disease
HK1075450A1 (en) heterocyclic compunds, process for their preparation and pharmaceutical compositions containing thenm and thier use in medicine
WO2005014572A8 (en) Pyrimidylpyrrole derivatives active as kinase inhibitors
WO2002064766A3 (en) Bax-responsive genes for drug target identification in yeast and fungi
Ahmadi et al. In vivo metal-catalyzed SeCT therapy by a proapoptotic peptide
WO2002102311A3 (en) Nanoparticles for treating targeted tissues and cells
EP1152002A4 (en) Pyrrole derivatives and cell death inhibitors
AU2003220773A1 (en) Pharmaceuticals comprising shikonins as active constituent
Alves et al. The patenting and technological trends in candidiasis treatment: a systematic review (2014-2018)
CN102459245A (en) Thioxanthene derivatives for the treatment of infectious diseases
WO2001002550A3 (en) Cell death related drug targets in yeast and fungi

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 67626/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000955415

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000955415

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000955415

Country of ref document: EP